Back to News
Market Impact: 0.28
XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%
Source: Nasdaq
Healthcare & BiotechProduct Launches
XORTX Therapeutics began drug-substance production and tablet manufacturing for XORLO, its gout-treatment candidate, to support the planned two-part XRX-OX clinical program. The manufacturing start represents a positive development milestone for the late-stage biotech and lifted shares in overnight trading, though clinical and regulatory execution risks remain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
XRTX0.58
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
- Federal budget deficit reaches $2T in first 11 months of fiscal year 2026, CBO reports
- Tesla eyes European freight market with long-delayed Semi truck
- Meet Ottava, J&J's surgical robot leading the healthcare giant into a lucrative new market